Levetiracetam (LEV) is a pyrrolidone derivative, approved 2000 in Europe. More recent reports seem to suggest its efficacy on generalised seizures in the context of idiopathic epilepsies. The aim of our study was to report on the efficacy and the tolerability of LEV monotherapy in idiopathic generalized epilepsy in an unselected group of adolescents who attended the epilepsy services of the participating hospitals in the period Jan 2002-Dec 2003. Our experience, albeit on a small sample, seems to suggest that LEV can be extremely effective and well tolerated as monotherapy in patients generalized seizures. Our encouraging results, if confirmed by blinded studies using appropriate randomisation, suggest that LEV has the potential to be considered as first-line treatment particularly in adolescent females with JME, given the well-known potentially teratogenic effect of sodium valproate.
|Translated title of the contribution||Efficacy and tolerability of Levetiracetam monotherapy in adolescents with idiopathic generalized epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 2005|
ASJC Scopus subject areas
- Clinical Neurology